Evidence map›Paper›PMID 29169030›Full record

ArticleAtherosclerosis2018

Lipoprotein-associated phospholipase A

Parveen K Garg, Faye L Norby, Linda M Polfus, Eric Boerwinkle, Richard A Gibbs, Megan L Grove, Aaron R Folsom, Pranav S Garimella, Kunihiro Matsushita, Ron C Hoogeveen and 1 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Lp-PLAScientific reports · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Parveen K GargDivision of Cardiology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. Electronic address: parveeng@med.usc.edu.
Faye L NorbyDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Linda M PolfusUniversity of Texas Health Sciences Center at Houston, Houston, TX, USA.
Eric BoerwinkleUniversity of Texas Health Sciences Center at Houston, Houston, TX, USA.
Richard A GibbsDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Megan L GroveUniversity of Texas Health Sciences Center at Houston, Houston, TX, USA.
Aaron R FolsomDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Pranav S GarimellaDivision of Nephrology-Hypertension, University of California San Diego, La Jolla, CA, USA.
Kunihiro MatsushitaDepartment of Epidemiology, The Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Ron C HoogeveenSection of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, TX, USA; The Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA.
Christie M BallantyneSection of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, TX, USA; The Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA.
The University of Texas Health Science Center at Houston · USHouston Methodist · USUniversity of Minnesota · USBaylor College of Medicine · USJohns Hopkins University · USUniversity of California San Diego · USUniversity of Southern California · US

Funding

The Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3M
Building on GWAS for NHLBI-disease: the CHARGE consortiumRC2HL102419 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BOERWINKLE, ERIC A. · 2009 to 2010
$27.6M
NHGRI NIH HHS U54 HG003273NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS RC2 HL102419
6 · The paper itself

Abstract

BACKGROUND AND

aimsResults from prospective studies evaluating the relationship between elevated lipoprotein-associated phospholipase A

methodsOur analysis included 9922 participants (56% female; 21% African-American; mean age 63 years) without baseline PAD at ARIC Visit 4 (1996-1998), who had Lp-PLA

resultsDuring a median follow-up of 14.9 years, we identified 756 incident cases of PAD. In analyses adjusting for age, race, and sex, each standard deviation increment in Lp-PLA

conclusionsWhile higher Lp-PLA

Indexed as

1-Alkyl-2-acetylglycerophosphocholine EsteraseAgedBiomarkersDisease ProgressionFemaleGenetic VariationHumansIncidenceMaleMiddle AgedPatient AdmissionPeripheral Arterial DiseasePrevalencePrognosisProspective StudiesRisk Assessment1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkersPLA2G7 protein, humanEpidemiologyInflammationLipoprotein-associated phospholipase A(2)Peripheral artery disease

Identifiers

PMID29169030
PMCPMC6392003
OpenAlexW2769178920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.